Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DP58GD
|
|||
| Drug Name |
BBP-631
|
|||
| Drug Type |
Gene therapy
|
|||
| Indication | Congenital adrenal hyperplasia [ICD-11: 5A71.01; ICD-10: E25.0] | Phase 1/2 | [1] | |
| Company |
Adrenas Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Steroid 21-hydroxylase (CYP21A2) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04783181) A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of the Safety and Efficacy of Gene Therapy for Congenital Adrenal Hyperplasia Through Administration of an Adeno-Associated Virus (AAV) Serotype 5-Based Recombinant Vector Encoding the Human CYP21A2 Gene. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Adrenas Therapeutics | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.